The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characterization of systemic therapy utilization in 274 patients with de novo metastatic breast cancer and effect of novel chemotherapeutic agents on survival.
R. A. Nelson
No relevant relationships to disclose
J. E. Mortimer
No relevant relationships to disclose
M. E. Dehaven
No relevant relationships to disclose
S. Onami
No relevant relationships to disclose
L. Bernstein
No relevant relationships to disclose
S. K. Pal
No relevant relationships to disclose